Previous 10 | Next 10 |
2023-06-11 09:51:51 ET Summary Shares of precision oncology concern Kinnate Biopharma Inc. (KNTE) have crashed 93% from their all-time high as long overdue data from a Phase 1 study failed to impress. The company is advancing a couple of early-stage compounds but has hit some bump...
2023-06-01 08:45:42 ET Palm Beach, FL – June 1, 2023 – FinancialNewsMedia.com News Commentary – Neurofibromatosis is a genetic condition that disrupts the cell growth in your nervous system, causing formation of tumors on nerve tissue. These formed tumor...
2023-05-21 10:56:57 ET Summary KNTE targets these two less-targeted BRAF classes. They have some clinical data, but data is not very strong. They have more cash than their market cap. Kinnate Biopharma ( KNTE ) develops small molecule kinase inhibitors to treat g...
2023-05-11 17:03:52 ET Kinnate Biopharma press release ( NASDAQ: KNTE ): Q1 GAAP EPS of -$0.73 beats by $0.01 . For further details see: Kinnate Biopharma GAAP EPS of -$0.73 beats by $0.01
Presented positive monotherapy dose escalation data for exarafenib, an investigational pan-RAF inhibitor, at the 2023 AACR Annual Meeting Provided update on ongoing exarafenib monotherapy dose expansion; data-informed strategy prioritizes enrollment in BRAF Class II-driven solid tumor...
2023-05-03 13:00:53 ET If you’re looking for the best penny stocks to buy, chances are that you’re looking for potential catalysts. This might come in the form of news headlines, social sentiment, speculation, or a mix of different catalysts. One that has stood out for inv...
2023-04-18 12:50:32 ET Gainers: BELLUS Health ( BLU ) +98% . Dermata Therapeutics ( DRMA ) +68% . Gamida Cell ( GMDA ) +53% . Allarity Therapeutics ( ALLR ) +45% . Esports Entertainment Group ( GMBL ) +35% . Altamira Therapeu...
2023-04-17 14:59:28 ET Kinnate Biopharma ( NASDAQ: KNTE ) said that the ~$231M in cash, cash equivalents, and investments on hand is enough to fund operations through early 2025. The company said it is also advancing two additional candidates into the clinic: KIN-7136 for ...
KIN-7136, a next generation brain-penetrant MEK inhibitor for MAPK-driven advanced adult solid tumors, is expected to enter the clinic in the second half of 2023 KIN-8741, a highly selective c-MET inhibitor designed to cover acquired resistance in non-small cell lung cancer and other ad...
Exarafenib was well-tolerated at substantial monotherapy exposures; only 3% (n=2/60) of patients discontinued therapy due to treatment-related adverse events Breadth of responses observed across tumor types and BRAF or NRAS alterations with a total of 8 partial responses in the monoth...
News, Short Squeeze, Breakout and More Instantly...
Kinnate Biopharma Inc. Company Name:
KNTE Stock Symbol:
NASDAQ Market:
Kinnate Biopharma Inc. Website:
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
EMERYVILLE, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) (“XOMA” or the “Company”), a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health, today announced th...
Cano Health Inc. Class A (CANOQ) is expected to report for Q4 2023 Cathay Pacific Airways Ltd. ADR (CPCAY) is expected to report for Q4 2023 NeuroSense Therapeutics Ltd. (NRSN) is expected to report for quarter end 2023-12-31 Bayerische Motoren Werke AG (BAMXF) is expected to report f...